The results revealed that the antibody levels of anti-RBD IgG, anti-NP1 IgG, anti-NP2 IgG, and anti-NP3 IgG in serum increased 3.27-fold [96.375 (95% CI 48.47 to 144.28) vs. 2193.25 (95% CI 1356.49 to 3030.01), p < 0.0001], 6.12-fold [89.81 (95% CI 71.34 to 178.28) vs. 3599.25 (95% CI 1034.46 to 3364.04), p < 0.0001], 3.79-fold [126.25 (95% CI 85.39 to 167.11) vs. 3307.11 (95% CI 1191.78 to 4702.45), p < 0.0001], and 4.52-fold [166.50 (95% CI 92.25 to 240.75) vs. 2324.36 (95% CI 1149.41 to 3156.31), p < 0.0001], respectively, compared with those before COVID-19 vaccination (Figure 2C). Here, LNP1 is linked to COVID-19.